Last reviewed · How we verify
Estradiol & medroxyprogesterone acetate
Estradiol & medroxyprogesterone acetate, marketed by Far Eastern Memorial Hospital, is a hormonal therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use for its indicated conditions. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Estradiol & medroxyprogesterone acetate |
|---|---|
| Sponsor | Far Eastern Memorial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- Intrauterine Stent Placement Following Hysteroscopic Septum Resection (NA)
- Estrogen Receptor Beta and Mood (PHASE2)
- Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency (NA)
- Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women (PHASE2)
- Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (PHASE3)
- A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment
- HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: